Alnylam Pharmaceuticals (ALNY) Competitors $246.27 -2.89 (-1.16%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends ALNY vs. GILD, VRTX, REGN, BIIB, UTHR, NBIX, INCY, BMRN, EXAS, and EXELShould you be buying Alnylam Pharmaceuticals stock or one of its competitors? The main competitors of Alnylam Pharmaceuticals include Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), and Exelixis (EXEL). These companies are all part of the "biotechnology" industry. Alnylam Pharmaceuticals vs. Gilead Sciences Vertex Pharmaceuticals Regeneron Pharmaceuticals Biogen United Therapeutics Neurocrine Biosciences Incyte BioMarin Pharmaceutical Exact Sciences Exelixis Alnylam Pharmaceuticals (NASDAQ:ALNY) and Gilead Sciences (NASDAQ:GILD) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, community ranking, risk, analyst recommendations, valuation, institutional ownership, profitability, earnings and dividends. Do insiders and institutionals hold more shares of ALNY or GILD? 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.7% of Gilead Sciences shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 0.3% of Gilead Sciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community favor ALNY or GILD? Gilead Sciences received 1332 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. Likewise, 76.88% of users gave Gilead Sciences an outperform vote while only 76.17% of users gave Alnylam Pharmaceuticals an outperform vote. CompanyUnderperformOutperformAlnylam PharmaceuticalsOutperform Votes113876.17% Underperform Votes35623.83% Gilead SciencesOutperform Votes247076.88% Underperform Votes74323.12% Which has more volatility & risk, ALNY or GILD? Alnylam Pharmaceuticals has a beta of 0.34, indicating that its stock price is 66% less volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.18, indicating that its stock price is 82% less volatile than the S&P 500. Which has higher earnings and valuation, ALNY or GILD? Gilead Sciences has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$1.83B17.37-$440.24M-$2.62-94.00Gilead Sciences$27.12B4.22$5.67B$0.091,020.44 Does the media prefer ALNY or GILD? In the previous week, Gilead Sciences had 9 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 41 mentions for Gilead Sciences and 32 mentions for Alnylam Pharmaceuticals. Gilead Sciences' average media sentiment score of 0.85 beat Alnylam Pharmaceuticals' score of 0.70 indicating that Gilead Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 11 Very Positive mention(s) 4 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Gilead Sciences 28 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Is ALNY or GILD more profitable? Gilead Sciences has a net margin of 0.45% compared to Alnylam Pharmaceuticals' net margin of -15.86%. Gilead Sciences' return on equity of 29.00% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-15.86% N/A -8.38% Gilead Sciences 0.45%29.00%9.83% Do analysts rate ALNY or GILD? Alnylam Pharmaceuticals currently has a consensus target price of $298.61, suggesting a potential upside of 21.25%. Gilead Sciences has a consensus target price of $97.96, suggesting a potential upside of 6.66%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Gilead Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 5 Hold rating(s) 19 Buy rating(s) 0 Strong Buy rating(s) 2.72Gilead Sciences 0 Sell rating(s) 11 Hold rating(s) 13 Buy rating(s) 3 Strong Buy rating(s) 2.70 SummaryGilead Sciences beats Alnylam Pharmaceuticals on 12 of the 19 factors compared between the two stocks. Get Alnylam Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ALNY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALNY vs. The Competition Export to ExcelMetricAlnylam PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$30.69B$6.37B$5.23B$8.96BDividend YieldN/A2.94%5.13%4.04%P/E Ratio-94.008.3083.3616.84Price / Sales17.37311.691,257.9179.09Price / CashN/A61.4443.8235.97Price / Book-139.936.055.324.79Net Income-$440.24M$154.90M$122.78M$224.99M7 Day Performance3.48%-1.73%-0.20%1.50%1 Month Performance3.51%2.68%3.71%4.68%1 Year Performance32.44%2.76%27.30%20.92% Alnylam Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALNYAlnylam Pharmaceuticals4.4437 of 5 stars$246.27-1.2%$298.61+21.3%+30.6%$30.69B$1.83B-94.002,100Analyst RevisionNews CoverageGILDGilead Sciences4.3905 of 5 stars$90.17+0.3%$97.96+8.6%+6.2%$112.38B$28.30B1,001.8918,000Insider TradeShort Interest ↑Analyst RevisionNews CoverageVRTXVertex Pharmaceuticals4.1833 of 5 stars$412.84+0.8%$490.38+18.8%-2.7%$106.32B$10.63B-207.465,400REGNRegeneron Pharmaceuticals4.664 of 5 stars$704.45+1.1%$1,037.33+47.3%-26.6%$77.41B$13.85B17.4311,900Analyst ForecastNews CoverageBIIBBiogen4.7143 of 5 stars$149.49+0.5%$230.00+53.9%-42.7%$21.78B$9.61B13.508,720Short Interest ↑UTHRUnited Therapeutics4.9245 of 5 stars$365.50+0.1%$378.36+3.5%+61.5%$16.32B$2.76B16.05980Analyst UpgradeInsider TradeShort Interest ↓News CoveragePositive NewsNBIXNeurocrine Biosciences4.9149 of 5 stars$142.68+1.3%$164.81+15.5%+4.5%$14.45B$2.24B38.251,200Insider TradeNews CoverageINCYIncyte4.7412 of 5 stars$72.84+3.3%$76.29+4.7%+17.0%$14.03B$4.08B520.322,524Analyst ForecastShort Interest ↓News CoverageBMRNBioMarin Pharmaceutical4.9993 of 5 stars$66.97-0.6%$94.20+40.7%-34.1%$12.76B$2.75B40.103,401Options VolumeNews CoverageEXASExact Sciences4.7666 of 5 stars$57.82+2.3%$72.94+26.1%-19.2%$10.70B$2.69B-49.426,600News CoverageEXELExelixis4.5431 of 5 stars$35.35-1.9%$33.75-4.5%+60.6%$10.10B$2.08B22.661,310Analyst ForecastShort Interest ↑Analyst RevisionNews Coverage Related Companies and Tools Related Companies Gilead Sciences Alternatives Vertex Pharmaceuticals Alternatives Regeneron Pharmaceuticals Alternatives Biogen Alternatives United Therapeutics Alternatives Neurocrine Biosciences Alternatives Incyte Alternatives BioMarin Pharmaceutical Alternatives Exact Sciences Alternatives Exelixis Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ALNY) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | SponsoredStunning Trump Exec Order LeakedMost people have no clue this unassuming facility exists. Yet the minute Donald Trump takes office... ...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredThe Biggest Money-Making Idea in My 43 Years in the Stock MarketBillionaires and top investors - including the late great Charlie Munger - and many more names you would recog...The Oxford Club | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowIt’s here. This is the moment we’ve been waiting for. The next 3-6 months in crypto will be absolutely life...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alnylam Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alnylam Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
